The present invention provides a method of assisting a determination of whether a subject is susceptible to infection by norovirus or whether a subject is susceptible to post-infection worsening, wherein this method contains a step of measuring the concentration of IgG antibody that is present in a sample originating from within the oral cavity of the subject.

The disclosure provides an assay for detecting if a subject is seropositive for SARS-CoV-2, or not, comprising incubating a biological sample from the subject with uninfected cells and SARS-CoV-2-infected cells, where the uninfected cells and the SARS-CoV-2-infected cells are distinguishable from each other, to form an admixture, and determining an amount of antibodies in the biological sample bound to the uninfected cells and to the SARS-CoV-2-infected cells, thereby determining whether the subject whose biological sample was tested is seropositive for SARS-CoV-2, or not.

Provided is a digital surface-enhanced Raman scattering (SERS) sensing platform which allows quantitative detection of a substance to be detected reliably and reproducibly with an excellent limit of detection in a large dynamic range, including: a surface-enhanced Raman scattering (SERS) active reagent which includes Raman active particles including a spherical plasmonic metal core, a plasmonic metal shell having a surface unevenness, and a self-assembled monolayer including a Raman reporter positioned between the core and the shell; a Raman spectroscopic detection unit which performs Raman mapping based on a Raman spectrum which is detected by irradiating the active reagent with an excitation light; and a digital signal analysis unit which analyzes a quantitative detection signal of a substance to be detected by a combination of a Raman signal intensity calculated from the Raman spectrum and a digital count calculated from the Raman mapping.

The disclosure is directed in part to variant capsid polypeptides that can be used to deliver payloads.

The application relates to a method and device for quantitatively analyzing the detection results of lateral flow-type test kits. Disclosed is a method for quantitatively analyzing the test results of a lateral flow-type test kit wherein the test kit includes a result area in which a control C-line region and a detection T-line region are set. The method includes: determining an analyte concentration range that the test kit can detect; diluting a sample into a plurality of sample dilutions having different pre-determined analyte concentrations within the determined analyte concentration range; applying each sample dilution having a pre-determined analyte concentration to a sampling well on the rapid test kit for the analyte, so as to obtain separate resulting images with different color intensities on the T-line region corresponding to different pre-determined analyte concentrations; calculating a corresponding color intensity index values for the T-line regions of each resulting image, respectively; and creating a continuous curve by fitting the corresponding plurality of color intensity index values to the plurality of different pre-determined analyte concentrations, wherein the corresponding analyte concentration can be obtained based on the color intensity index value at any point on the continuous curve.

The invention relates to method and kits for highly specific isolation of surface marker displaying agents from the central nervous system by targeting at least two surface markers. The invention further relates to methods and kits for analyzing surface marker displaying agents and their contents.

The present invention relates to a monoclonal antibody or an antigen-binding fragment thereof, wherein the monoclonal antibody or the antigen-binding fragment thereof reacts with a structural protein of SARS-CoV-2 specifically, and the structural protein of SARS-CoV-2 is at least one selected from the group consisting of S-protein, N-protein, M-protein, and E-protein and a hapten, wherein the hapten that reacts with an antibody that reacts with a protein of SARS-CoV-2 specifically, and the protein of SARS-CoV-2 is at least one selected from the group consisting of S-protein, N-protein, M-protein, and E-protein.

A concentration determination method includes the following steps. A sample fluid having a target material therein is diluted with a 1.sup.st dilution factor to an N.sub.th dilution factor to form a 1.sup.st sample to an N.sup.th sample. A bio-sensing integrated circuit having a 1.sup.st assay to an N.sup.th assay is provided. The 1.sup.st sample to the N.sup.th sample are respectively applied to the 1.sup.st assay to the N.sup.th assay. A bio-sensing process is performed on the 1.sup.st sample to the N.sup.th sample to obtain a 1.sup.st measurement value to an N.sup.th measurement value. The 1.sup.st measurement value to the N.sup.th measurement value are compared with a threshold value to determine a threshold dilution factor, which corresponds to a largest dilution factor that has a measurement value higher than the threshold value. A concentration of the target material is calculated based on the threshold dilution factor and a limit of detection.

The present invention relates to improved single domain antibodies that target SARS-CoV-2, the use of said single domain antibodies in treating and/or preventing coronavirus, as well as the use of said single domain antibodies in the detection and diagnosis of coronavirus using various methods, assays and kits.

Compositions and methods useful for vaccinating for or preventing a Coronavinus infection, antibody screening, and variant prediction are provided. The present disclosure also provides for compositions and methods useful for sera diagnostics, treatment screening, and methods of making the compositions described herein.